CLINICAL
TRIALS:
Consents
CTU
Newsletter 3/2008
Click
trial to get more information
Longitudinal
Study of Ocular Complications of AIDS :LSOCA
A
Double Blind Phase II Study of Multiple Doses of Palifermin
(rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte
Recovery in Subjects on Potent Antiretroviral Therapy
with Plasma HIV-1 RNA Levels =200 copies/mL.:
A5212
Optimizing
Vaccine Responsiveness in HIV-1 and HCV Infections
and Identifying Determinants of Responsiveness: A
Pilot Study:
A5232
A
Phase II, Randomized, Placebo-Controlled, Double-Blind
Study of Minocycline in the Treatment of HIV-Associated
Cognitive Impairment :
A5235
The
Optimized Treatment that Includes or Omits NRTIs (OPTIONS)
Trial: A Randomized Strategy Study for HIV-1-Infected
Treatment-Experienced Subjects Using the cPSS to Select
an Effective Regimen:
A5241
A
Multicenter, Open-Label, Controlled Phase II Study
to Evaluate Safety and Immunogenicity of MVA-BN®
(IMVAMUNETM) Smallpox Vaccine in 18-55 Year Old Naive
and Previously Vaccinated HIV Infected Subjects With
CD4 Counts > 200 – 500/µl: POX-011
A
Phase 1B, Randomized, Placebo Controlled, Double Blind
Study to Determine the Safety, Viral Suppression Potential,
Pharmacokinetics and Immune Modulatory Effects of
the Treatment with Aprepitant (EMEND) in HIV Infected
Patients:EMEND
Vicriviroc
in Combination Treatment With an Optimized ART Regimen
in HIV-Treatment Experienced Subjects:
VICTOR-E4
Pending
Trials:
A
Phase III, Randomized, Double-blind Study of TMC278
75mg vs Efavirenz 600mg qd in Combination with a Fixed
Background Regimen Consisting of Tenofovir Disoproxil
Fumarate and Emtricitabine in Antiretroviral-Naive
HIV-1 Infected Patients:
TMC278
If
you have any questions regarding these studies, Please
call 215-349-8092
updated
02/27/08
